​

Pascoe and his corrupted cronies is leaving. Hopefuply Mangless and his team bring in a solid CEO for us. Our future is bright. Stay tune.

https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-announces-fda-acceptance-ind-application

Here's the back story. We were in a proxy battle for the future of our company. It was the 3 time loser of a CEO Pascoe and his cronies vs our activist investor Daniel J. Mangless. Against all odds, this is the final results. It's about time for a change of the old and incompetent guards.

​

Tuesday, March 7, 2023, at 8:30 a.m. ET

https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-report-fourth-quarter-and-full-year-2022

New name, Greek for “zebra,” is the internationally-recognized symbol for the rare disease community

Branding reflects Company’s commitment to making rare disease therapies available through its research, development, and commercialization efforts

The Company’s common shares will trade on The Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting on or about March 1, 2023https://investors.zevra.com/news-releases/news-release-details/correction-kempharm-announces-corporate-name-change-zevra